



### Jim Greenwood

Senior Policy Advisor  
CHAIR, LIFE SCIENCES POLICY PRACTICE

[jim.greenwood@dlapiper.com](mailto:jim.greenwood@dlapiper.com)

#### Washington, DC

T: +1 202 799 4381

F: +1 202 799 5158

Jim Greenwood is Chair of DLA Piper's Life Sciences Policy group. He advises clients on a variety of legislative, regulatory and policy issues impacting the Healthcare and Life Sciences sectors.

Jim represented Pennsylvania's Eighth Congressional District from 1993 to 2005. During his time in Congress, he was a senior member of the Energy and Commerce Committee and widely viewed as a leader on healthcare and the environment. He crafted legislation to reform the Food and Drug Administration, to create the pediatric exclusivity and pediatric autism research acts and he led the fight in Congress to allow stem cell research to be conducted by US scientists to treat disease.

From 2001 to 2004, Jim served as chair of the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations. In this role, he led Investigations into corporate governance at Enron, Global Crossing and WorldCom, to reform the NIH and into waste and fraud in federal government agencies. Before his election to Congress, from 1981 to 1992, Jim served in the Pennsylvania General Assembly, including six years in the State House and six years in the State Senate.

Prior to joining DLA Piper, Jim served as president and CEO of BIO, a trade association that represents 1,000 biotechnology companies, academic institutions, and state biotechnology centers across the US and in more than 30 countries. Its members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, as well as other major investor and business conferences across the world.

*Jim Greenwood is not a lawyer.*

- Riidanratkaisu
- Healthcare

## Koulutus

- B.A., Dickinson College

## Publications

### **The moral imperative: Balancing innovation, regulation and prescription drug availability**

21 March 2022

At the Intersection of Science and Law Podcast Series

Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky to discuss the importance of – and complications in - balancing biopharmaceutical innovation, industry regulations and prescription drug availability.

---

## Events

### Previous

#### **2021 Healthcare Leadership Conference: Day 3 - Washington roundtable**

10 March 2021 | 12:00 PM - 3:30 PM ET

2021 Healthcare Leadership Conference

---

#### **Policy priorities and insights: The road ahead post-election**

13 January 2021 | 12:00 - 1:15 ET

Webinar

---

#### **2020 BioHealth Capital Region Virtual Forum**

19 October 2020 | 4:30 - 5:00 EDT

Webinar

---

## UUTISET

---

### **DLA Piper announces new practice leadership**

18 February 2022

DLA Piper is pleased to announce several changes to sub-practice leadership in its Finance, Corporate, Private Equity, Regulatory and Government Affairs, and Litigation practices.

---

### **Former Congressman Jim Greenwood joins DLA Piper as senior policy advisor, adding significant strength to growing life sciences policy and regulatory group**

4 August 2020

DLA Piper announced today that former US Representative Jim Greenwood has joined the firm's Litigation and Regulatory practice as a senior policy advisor based in Washington, DC.

